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LABORATORY INVESTIGATION
PDGF-receptor localizes to mesangial, parietal epithelial, and
interstitial cells in human and primate kidneys
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and DANIEL F. BOWEN-POPE
Departments of Pathology and Medicine, University of Washington School of Medicine, Seattle, Washington, USA
PDGF-receptor localizes to mesangial, parietal epitheial, and intersti-
tial cells in human and primate kidneys. There is evidence that platelet
derived growth factor (PDGF) is a mediator of proliferative changes in
renal arteries and mesangium in human disease, in the mesangium in
experimental mesangial proliferative glomerulonephritis, and in the
interstitium in a rodent model of angiotensin II mediated hypertension.
We utilized a monoclonal antibody to the a-subunit of the PDGF-
receptor to localize constitutive expression of this receptor in human
and nonhuman primate tissues. Tissues were fixed in cold 2 or 4%
paraformaldehyde, and immunohistochemical techniques both at the
light microscopic level and immunoelectron microscopy were em-
ployed. In the glomerulus, there is widespread expression of this
molecule by mesangial cells, and there is frequent expression on the
apical and lateral surface of parietal epithelial cells. There is also
widespread expression of this molecule by cortical and medullary
peritubular interstitial cells, but not by glomerular or peritubular
capillary endothelium or other renal parenchymal structures. The
identification of receptors capable of binding PDGF B-chain at each of
these sites: (I) provides a basis for PDGF mediated mesangial prolifer-
ation in human disease; (2) provides a basis for PDGF mediated
interstitial cell migration and/or proliferation and/or activation at sites
of tubulointerstitial injury; and (3) suggests that glomerular parietal
epithelial cells may be responsive to stimulation by PDGF.
Platelet-derived growth factor (PDGF) mediates multiple
cellular activities in a variety of cell types via specific receptors.
These activities include stimulation of cell proliferation [1, 2],
stimulation of cell migration, particularly of mesenchymal cells
such as smooth muscle cells and fibroblasts [3—7], and induction
of connective tissue matrix synthesis and deposition both in
vitro and in the course of wound healing [8—11]. Platelet-derived
growth factor is a covalent dimer of two subunit chains desig-
nated A-chain and B-chain, which exists in three naturally
occurring dimeric isoforms (PDGF-AA, PDGF-AB, and PDGF-
BB). PDGF binds to cells by cell surface receptors which
function as noncovalent dimers of two subunits, designated as
PDGF receptor a-subunit (PDGFRa) and the PDGF receptor
/3-subunit (PDGFRI3), in such a way that cells expressing only
PDGFR/3 are able to bind only PDGF-BB and cells expressing
PDGFRa are able to bind all forms of PDGF [12].
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Recent studies have provided evidence that PDGF B-chain
has an important role both in experimental and human nephri-
tis. In the rat model of mesangial proliferative glomera lonephri-
tis induced with anti-Thy! antibody, up-regulated synthesis of
PDGF B-chain and the PDGF-f3 receptor by mesangial cells
occurs at times of peak cell proliferation [13, !4j and the cell
proliferation occurring at day four of this model can be signif-
icantly reduced by administration of a neutralizing anti-PDGF
B-chain antiserum [15]. Up-regulation of PDGF A- and B-chain
mRNA has also been demonstrated in a murine model of
dextran induced IgA nephropathy [16]. Immunohistochemical
evidence for participation of PDGF in human disease has been
provided by studies which have localized PDGF to mesangial
areas in IgA nephropathy and other mesangial proliferative
glomerulonephndities [16, 17], and by studies of expression of
PDGF-receptor in which the receptor expression appears to
have been upregulated in arterial vessels involved in transplant
rejection as well as in glomeruli in cases of mesangial prolifer-
ative glomerulonephritis [18].
Although PDGFR expression in normal human kidneys has
been reported, the exact cellular localization of these PDGFRs
in normal human kidney has not been well defined. Fellström
detected weak mesangial expression of PDGFR/3 in 3/6 normal
human kidneys by immunohistologic techniques on frozen
tissue sections, and apparently found no normal staining within
the cortical interstitium or other glomerular structures [18]. In a
survey study of frozen human tissues, Franklin et at found
mesangial localization of PDGFR/3 in eight kidneys [1 9J, but the
immunocytochemical approaches reported to date do not allow
more precise assignment of expression of this protein to specific
cell types, particularly within the interstitium. In the present
study, we have utilized a well characterized monoclonal anti-
body to PDGFR/3 to localize its expression in normal human
and primate kidneys. We demonstrate by both immunohisto-
logic and, for the first time, immunoelectron microscopic tech-
niques that PDGFR/3 is constitutively expressed by mesangial
cells and parietal epithelial cells in the glomeruli of humans,
macaques, and baboons. We also show widespread constitutive
expression of PDGFR/3 by cortical and medullarv interstitial
cells. These latter findings provide evidence that these intersti-
tial cells are likely to be responsive to PDGF, which may thus
mediate at least in part the migration and activ ation of these
cells at sites of interstitial injury and fibrosis.
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Methods
Source of tissue
Normal human kidney tissue (N = 25) was obtained fresh
from uninvolved portions of kidneys surgically resected for
localized renal cell carcinoma, or from cadaver donor kidneys
unable to be utilized for transplantation. Normal primate kid-
neys, baboon (N = 4) and macaca nemestrina (N = 6), were
obtained fresh from the Regional Primate Research Center at
the University of Washington. The tissue was fixed overnight in
cold 2% or 4% paraformaldehyde in phosphate buffer, trans-
ferred to 30% sucrose in 0.1 M phosphate buffer, equilibrated
overnight at 4°C, and snap frozen in OCT compound (Miles,
Inc., Elkhart, Indiana, USA).
Immunohistochemistry
Murme monoclonal antibody PR7212 has been previously
characterized by Western blotting and competitive binding
studies and shown to recognize the f3 subunit of the PDGF
receptor [20]. The epitope recognized by this antibody is stable
in paraformaldehyde fixed tissues [21].
Frozen sections of 2% or 4% paraformaldehyde fixed tissue
were hydrated in PBS and then incubated overnight at 4°C with
antibody 7212, washed, and processed using streptavidin-biotin
immunoperoxidase method with biotinylated horse-anti-mouse
IgG (Vector Labs, Burlingame, California, USA) as the second-
ary antibody, Vectastain Elite ABC (Vector Labs) as the
detection system and 3,3'-diaminobenzidine (DAB) as the chro-
mogen. Endogenous peroxidase was blocked by incubating the
slides in 3% hydrogen peroxide following incubation with the
biotinylated secondary antibody. The sections were counter-
stained with methyl green, dehydrated and coverslipped.
For all samples, a negative control consisted of substitution
of the primary antibody with both irrelevant isotype-matched
murine monoclonal antibodies and PBS.
Immunoelectronmicroscopy
Frozen, 4% paraformaldehyde fixed kidneys were sectioned
at 6 tm and sections adhered to APTS coated slides and air
dried for 30 minutes. The sections were then stained by
hydrating in PBS for 15 minutes, incubated in 0.05% sodium
borohydride in PBS at 4°C for 60 minutes to reduce free
aldehyde groups, rinsed and then incubated with antibody
PR7212 or control antibody at 4 j.g/ml in PBS containing 2%
BSA overnight at 4°C. The slides were then processed as above
using the streptavidin-biotin immunoperoxidase method. After
washing in distilled water, sections were reacted with 2% 0504
for one hour at room temperature, rinsed and then dehydrated
through graded ethanols and into propylene oxide. Sections
were then infiltrated with a 50/50 mixture of PolyBed (Poly-
Sciences, mc, Warrington, Pennsylvania, USA) and propylene
oxide for one hour. Beem capsules were filled with PolyBed,
inverted over the sections, infiltrated overnight and then poly-
merized at 55°C for 48 hours. The blocks were removed by
heating the slide briefly and quickly snapping off the capsule.
Thin, 0.1 micron sections were cut and mounted on grids and
examined in a Philips 410 electron microscope.
Results
Immunohistochemistry
Results of the immunohistocheinical studies in baboons,
macaques, and humans are identical and will be described
together. In all cases, there is diffuse expression of PDGFRj3
within mesangial areas (Fig. 1A, B). Expression of PDGFRJ3 by
parietal epithelial cells was also frequently detected (Fig. 1A).
There was no evidence of PDGFR/3 expression by visceral
epithelial cells, cells of the juxtaglomerular apparatus, or hilar
vasculature.
There was also widespread expression of PDGFRI3 by cells
within the cortical and medullary interstitium (Fig. lB—D).
Arterial vessels showed no detectable expression of PDGFRI3
by either endothelial cells or smooth muscle cells (Fig. 1C).
Prominent staining of arterial adventitial connective tissue cells
was observed. Tubular cells were uniformly negative.
At this level of fixation and resolution, required for preser-
vation of the epitope recognized by the 7212 antibody, it is not
possible to clearly differentiate expression by endothelial cells
lining the peritubular capillaries from expression by interstitial
fibroblasts.
Immunoelectron microscopy
Glomeruli. Immunoelectron microscopy confirmed immuno-
histochemical studies demonstrating that PDGFRI3 expression
is confined to the mesangium and parietal epithelial cells (Figs.
2, 3). There is no extension of reactivity to the monoclonal
antibody to basement membranes of the peripheral capillaries
walls, or to visceral epithelial cells. There is peroxidase product
indicative of PDGFRI3 expression at spaces where mesangial
cells about mesangial channels and there is accordingly perox-
idase product in those areas where mesangial cells are exposed
to the capillary lumen. In those sites, one cannot absolutely
exclude regional expression of PDGFR/3 by endothelial cells.
However, in each case where the cell borders of endothelial
cells overlying these regions can be distinguished from under-
lying mesangial cells, the expression of PDGFRJ3 can be clearly
seen to be confined to the mesangial cells (Fig. 2). In no case
was PDGFR13 expression identified in the fenestrated portions
of endothelial cells lining the peripheral capillary loops.
Iminunolocalization of PDGFRI3 expression at the ultrastruc-
tural level also revealed uniform, distinct staining of the apical,
and at times lateral, cell surface of parietal epithelial cells (Fig.
3). No evidence of expression at the basal cell surface was
identified.
Interstitium. Human tissue fixed in glutaraldehyde and pre-
pared for transmission electron microscopy by conventional
techniques is used to illustrate the typical appearance of cortical
interstitial cells, as seen in Figure 4. Human cortical interstitial
cells, like those described in rodents [22, 23], are characterized
by their long, thin cell processes, focally prominent rough
endoplasmic reticulum, the absence of other distinctive cell
organelles, and the absence of cell junctions. They are without
obvious attachment to tubular basement membranes, tubular
epithelial cells, or the peritubular capillaries, although the
processes at times appear to extend in close proximity to the
tubular basement membranes.
Immunoelectron microscopy shows that it is this interstitial
cell type and not peritubular capillary endothelium, tubular
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Fig. 1. A. Human kidney. PDGFRI3 expression in the glomerulus is typically present diffusely within the mesangium, and can also be seen focally
on the apical surface of parietal epithelial cells (arrow). Surrounding interstitium contains a population of PDGFR/3 expressing cells. 480x. B.
Baboon kidney. There is striking localization of PDGFRI3 to mesangial areas. Glomeruli in subhuman primates normally demonstrate the wider
mesangial regions seen here, as compared with human kidneys. Widespread expression of PDGFR/3 by cortical interstitial cells is also apparent.
240x. C. Baboon kidney, Arcuate artery shows no detectable expression of PDGFR/3 by endothelial cells or smooth muscle cells comprising the
vessel intima and media. A population of adventitial connective tissue cells is strongly positive, as are the adjacent interstitial cells. 240x. D.
Human medulla. The interstitium shows diffuse expression of PDGFR/3 by dark staining spindled cells throughout the intertubular space. Adjacent
tubular epithelium is consistently negative. In some areas, PDGFR/3 expressing cells can be localized to regions of the interstitium located between
peritubular capillaries and tubular segments. 960x.
structures, or occasional interstitial leukocytes, which regularly
express PDGFRf3 (Fig. 5). Our studies indicate the presence
PDGFRJ3 diffusely with no evidence of polar distribution of the
receptor in these cells.
Controls. Substitution of an irrelevant isotype matched mono-
clonal antibody as well as PBS for primary antibody PR7212
abolished all specific staining (Fig. 6).
Discussion
It has been shown that mesangial cells in vitro are responsive
to PDGF, which can induce mesangial cell proliferation, migra-
tion, synthesis of matrix components, and stimulate further
production of this peptide by the mesangial cells themselves [2,
13—15, 24, 25]. Rat mesangial cells in vivo will also proliferate in
response to exogenous infusion of PDGF (J. Floege, et al,
unpublished observations). Human mesangial cells in vitro have
been shown to express PDGFRp, although some levels of
PDGF a receptor can also be demonstrated [26]. In addition,
PDGF and PDGFRf3 are expressed in mesangial regions in both
experimental and human mesangial proliferative glomerulone-
phritis [16—18], and inhibition of PDGF with anti-PDGF anti-
body in a rat model of acute, severe mesangiolytic injury
reduced the subsequent cell proliferation [15]. This has sug-
gested that human mesangial cells in viva express physiologi-
cally significant levels of the PDGF receptor. This study dem-
onstrates the unequivocal localization of PDGFR/3 to normal
human and nonhuman primate mesangial cells, and so provides
further evidence in support of the premise that mesangial
binding of PDGF is an important part of the response to
glomerular injury in humans.
This precise localization is consistent with the apparent
mesangial localization of PDGFRJ3 expression previously ob-
served by light microscopy on frozen sections of human kidney
[19]. However, because of the limited resolution afforded by
studies of unfixed tissue, those studies could not clearly distin-
guish mesangial from endothelial expression in the glomerulus.
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Fig. 2. Immunoelectron microscopy of a human glomerulus. PDGFR/3
expression is confined to the mesangium, (M) while glomerular capillary
endothelium (E) and visceral epithelial cells demonstrate no expression.
5150x.
This is an important issue because in some organs, such as the
brain, it has been suggested that PDGFRf3 may be expressed by
some capillary endothelial cells [27, 281. In this study, the use of
immunoelectron microscopy establishes that it is the mesangial
cell exclusively that constitutively expresses PDGFRf3. Our
studies found no evidence of PDGFR/3 expression by the
endothelial cells of the glomerulus. This finding provides a
logical extension of our studies of human fetal kidney, where
we have shown that expression of PDGFRf3 is uniformly
present in the mesangium of differentiated glomeruli [211.
Unlike some other proteins apparently produced by mesangial
cells in human kidneys in utero, such as a smooth muscle actin,
PDGF B-chain, and possibly Factor VIII related antigen, which
appear to undergo extensive downregulation prior to maturity
[21], PDGFR/3 expression remains readily detectable by immu-
nohistochemical techniques. In contrast to the studies of Fell-
strom et al [18], this study indicates that mature human mesan-
gial cells express detectable levels of the PDGFRb in histologic
sections prior to induction of any disease state; it would then
appear that this basal expression of the PDGF receptor may be
upregulated in disease settings. Based on our understanding of
rodent models of glomerular immune and noriimmune glomer-
ular injury [13, 25], and the suggestive findings of Fellström et
al [181, it is likely that modulation of PDGFRp expression is an
important mediator of human glomerulopathy.
A second finding of interest is the demonstration of PDGFR/3
expression at the surface of glomerular parietal epithelial cells.
Little is known about the functional activities of these cells, and
their interactions with other cells of the glomerulus is an area
that is largely unexplored. Recently, our group has shown that
visceral epithelial cells in the rat produce PDGF B-chain but not
PDGFR/3 as a response to cell injury induced by passive
Heymann nephritis [29]. Some proliferation of parietal epithe-
hal cells was noted in that study, although the parietal epithelial
cell is not thought to be a direct target of immune injury in that
model. Those findings, and the present demonstration of
PDGFR/3 on parietal epithelial cells, suggest a potential inter-
action between glomerular epithelial cells that is mediated by
local, paracrine release of PDGF B-chain by visceral epithelial
cells and binding of this peptide to its receptor on parietal
epithelial cells.
The constitutive expression of PDGFR3 by normal human
and primate renal interstitial cells is the third principal finding of
this study. There are currently no known specific cellular
markers of renal interstitial cells that distinguish such cells from
other mesenchymal cells within the kidney parenchyma. This
study suggests PDGFR may be such a marker in vivo. As in
the mesangium, this observation is an important extension of
our observations in human fetal kidneys, where it was shown
that a diffuse population of mesenchymal interstitial cells ex-
press PDGFRf3 [21]. In the mature kidney, PDGFRI3 expression
is widespread and generally uniform along the cell surface of
those interstitial cells having features of fibroblasts, that is, with
spindled cell shape, focally prominent rough endoplasmic retic-
ulum and absent cell attachment structures. One result of this
rather uniform staining of cell borders is that the immunohisto-
chemical and immunoelectron microscopic studies illustrate to
a degree greater than can be appreciated by unmodified trans-
mission electron microscopy the extent to which the cell bodies
of interstitial fibroblasts extend and course through the intersti-
tial parenchyma, often in parallel with the peritubular capillar-
ies. This immunoelectron microscopic localization of PDGFR
to the interstitial cells rather than peritubular capillaries in this
study might be considered a somewhat unexpected finding that
contrasts with evidence from brain tissue which points to
capillary endothelium as the site of PDGFR/3 expression [27,
28].
What role PDGFR/3 expression might be playing in tubulo-
interstitial biology or disease is at present highly speculative.
Much less is known about the activities of growth factors within
the interstitium as compared with the glomerulus, and there are
currently no disease models of tubulo-interstitiai injury in which
a role for PDGFRJ3 has been tested and established. However,
in angiotensin II mediated injury in rats, interstitial fibrosis,
type IV collagen deposition and tubular cell proliferation has
been associated with increased PDGF expression in interstitial
areas [30]. In this model the associated increase in PDGF
expression was also correlated with phenotypic changes of
interstitial cells which demonstrated a smooth muscle actin
expression and proliferation of a proportion of these actin-
expressing cells [30].
Despite the current paucity of relevant disease models, but
given what is known of PDGF biology, some investigators have
already offered hypotheses that link PDGF to renal interstitial
fibrogenesis [31—33]. Additional evidence to support a role for
PDGF in this type of response to injury comes from studies of
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Fig. 3. Macaque kidney. PDGFR/3 is
expressed at apical and lateral cell surfaces of
parietal epithelial cells (P). Visceral epithelial
cells (V) and their foot processes, and
capillary endothelium show no expression.
Disruption of the capillary basement
membrane is a sectioning artifact, where the
capillary wall has left the plane of section.
Portions of a dislodged parietal epithelial cell
are present in the urinary space (US).
Abbreviation: C, capillary lumen. 6050x.
wound healing in other sites such as the skin, where PDGF
responsive cells, presumably expressing PDGFR, can acceler-
ate the repair process [9—111. Preliminary studies in our labora-
tory suggest that PDGFRI3 expressing cells can accumulate in
sites of tubulo-interstitial injury, but it has not yet been possible
to ascertain whether these cells migrate from other portions of
the renal interstitium, migrate from other organs via the circu-
lation, or represent a locally derived, proliferating population of
cells (C.E. Alpers, unpublished observations).
In this regard, it has been increasingly accepted that the
extent of tubulo-interstitial scarring is the principle determinant
of residual renal functional reserve in human parenchymal renal
disease, regardless of whether the glomerular, vascular, or
tubulo-interstitial compartments were the primary sites of in-
jury [31—34]. Little is known about the specific mechanisms by
which fibroblasts and other mesenchymal cells may migrate to
or proliferate at sites of interstitial fibrosing injury and then
participate in this process of matrix accumulation and scarring.
Constitutive expression of PDGFR)3 by interstitial cells, cells
that have been identified as "cortical fibroblasts" or cortical
"type one cells" by others [22, 23], suggests a potential
mechanism by which these cells can be recruited to sites of
injury. It is possible that release of PDGF, perhaps by infiltrat-
ing cells such as monocytes/macrophages and platelets which
are known to localize in areas of tubulo-interstitial injury [30,
35—38], or alternately by adjacent tubular epithelial cells [39],
serves as a stimulus to recruit and possibly activate interstitial
fibroblasts at these areas of injury.
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Fig. 4. Human kidney. Transmission electron micrograph of the tubulo-interstitium showing tubular epithelial cells with prominent mitochondria
and interdigitating baso-lateral membranes, peritubular capillaries (C) lined by endothelium, and a central, spindled cortical interstitial cell with
prominent rough endoplasmic reticulum (arrows) and absent cell junctions. 6150x.
Fig. 5. Macaque kidney. PDGFRJ3 is expressed diffusely by a cortical interstitial cell like that illustrated in Figure 4, while adjacent collagen matrix
and capillary endothelium show no expression of the receptor. Abbreviation: C, Capillary. 8600x.
One surprising and important observation in this study was
the failure to demonstrate PDGFRp expression by smooth
muscle cells in normal renal arteries. Observations in vitro
indicate that vascular smooth cells are responsive to PDGF
B-chain, and therefore should express PDGFRI3 [1]. The stud-
ies of Fellström et a!, are of particular interest in that up-
regulated expression of PDGFR/3 in injured renal arteries was
demonstrated [18]. Taken together, the evidence suggests
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Fig. 6. Human kidney. Substitution of an irrelevant monoclonal antibody for the primary antibody used in Figures 1 through 5 shows absence of
specific staining of mesangial cells and parietal epithelial cells (A) and interstitial cells (B). Abbreviations are: M, Mesangium; C, glomerular
capillary lumen; P, parietal epithelial cell; T, tubule; I, interstitial cell; PC, peritubular capillary. A: 5800x. B: 9100x.
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PDGF B-chain may mediate part of the arterial response to
injury, while a trophic function for this growth factor in
undamaged portions of the vasculature is unlikely. This study
did not address renal expression of PDGF a receptor, which
may be important in vascular smooth muscle cells, because
reagents suitable to address this area in fixed tissue are not yet
available.
Methods to obtain populations of renal interstitial cells from
rabbits and humans and maintain them in culture have recently
been reported [40, 41]. Some of these studies indicate rabbit
medullary fibroblasts, but not cortical fibroblasts, may be
responsive to PDGF [401; this stands in contrast to this study
which indicates human and primate cortical and medullary
fibroblasts are likely to be responsive to PDGF. When cultured
human renal interstitial cells become more widely characterized
and available, it should be possible to investigate the respon-
siveness of these cells to PDGF as well as other migration and
growth regulatory molecules and cytokines. Understanding
these relationships may eventually allow development of ther-
apeutic strategies that might interrupt processes of progressive
interstitial injury, akin to recent successful approaches to
ameliorate specific growth factor effects in experimental gb-
merulonephritis [15, 421.
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